A Retrospective and Prospective Non-interventional Open Label Study to Assess the Real Life of Treatment-naive Patients With Wet Age-related Macular Degeneration in Routine Clinical Practice in France and Starting an Anti VEGF Therapy With Aflibercept

Trial Profile

A Retrospective and Prospective Non-interventional Open Label Study to Assess the Real Life of Treatment-naive Patients With Wet Age-related Macular Degeneration in Routine Clinical Practice in France and Starting an Anti VEGF Therapy With Aflibercept

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms RAINBOW
  • Sponsors Bayer
  • Most Recent Events

    • 30 Aug 2017 According to a Bayer media release, results from this trial will be presented at the European Society of Retina Specialists (EURETINA) Congress 2017.
    • 01 Apr 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 24 Nov 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2019 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top